CELG - 3 Things In Biotech July 1: Acceleron's Big Break Astellas Solidifies Cellectar Has A Chance?
Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Acceleron reaches for the gold in a pivotal trial
Company: Acceleron (XLRN) and Celgene (CELG)
Therapy: Luspatercept
Disease: Low- to intermediate-risk myelodysplastic syndrome ((MDS))
News: XLRN and CELG announced positive top-line data from their phase 3 MEDALIST trial, stating that their TGF-beta trapper luspatercept achieved a "highly statistically significant" improvement in the primary endpoint, which was transfusion independence at 8 weeks (you can